Cited 38 times in
Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2015-01-06T17:17:06Z | - |
dc.date.available | 2015-01-06T17:17:06Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1743-7555 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/99688 | - |
dc.description.abstract | AIMS: We evaluated and compared the safety and efficacy of sunitinib in Asian and non-Asian patients with metastatic renal cell carcinoma enrolled in a previously reported global expanded access program. METHODS: Previously treated and treatment-naïve patients received open-label sunitinib at a starting dose of 50 mg/day for 4 weeks, followed by 2 weeks off treatment, in repeated 6-week cycles. Safety was assessed regularly, tumor measurements were performed per local practice, and survival data collected where possible. RESULTS: Data were available for 212 Asian patients from Asian sites (Asian-A), 113 Asian patients from non-Asian sites (Asian-O) and 4046 non-Asian patients. The most common grade 3/4 treatment-related adverse events were neutropenia, thrombocytopenia, hand-foot syndrome, diarrhea, asthenia and fatigue. The incidence of many adverse events was greater in Asian-A than in Asian-O or non-Asian patients. Sunitinib efficacy was comparable between Asian and non-Asian patients, with an objective response rate of 18% versus 14%; median progression-free survival of 8.7 versus 10.9 months; and overall survival of 18.9 versus 18.4 months, respectively. CONCLUSIONS: Sunitinib demonstrated tolerable safety and similar efficacy in Asian and non-Asian patients. Geographic differences in the reported frequency of specific adverse events were noted across Asian patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 237~245 | - |
dc.relation.isPartOf | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage* | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Carcinoma, Renal Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Renal Cell/ethnology | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Indoles/administration & dosage* | - |
dc.subject.MESH | Indoles/adverse effects | - |
dc.subject.MESH | Kidney Neoplasms/drug therapy* | - |
dc.subject.MESH | Kidney Neoplasms/ethnology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Pyrroles/administration & dosage* | - |
dc.subject.MESH | Pyrroles/adverse effects | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Se-Hoon Lee | - |
dc.contributor.googleauthor | Yung-Jue Bang | - |
dc.contributor.googleauthor | Paul Mainwaring | - |
dc.contributor.googleauthor | Christina Ng | - |
dc.contributor.googleauthor | John W-C Chang | - |
dc.contributor.googleauthor | Philip Kwong | - |
dc.contributor.googleauthor | Rubi K Li | - |
dc.contributor.googleauthor | Virote Sriuranpong | - |
dc.contributor.googleauthor | Chee-Keong Toh | - |
dc.contributor.googleauthor | Jinyu Yuan | - |
dc.contributor.googleauthor | Susan Pitman Lowenthal | - |
dc.contributor.googleauthor | Hyun C Chung | - |
dc.identifier.doi | 10.1111/ajco.12163 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00257 | - |
dc.identifier.eissn | 1743-7563 | - |
dc.identifier.pmid | 24576311 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/ajco.12163/abstract | - |
dc.subject.keyword | Asian | - |
dc.subject.keyword | metastatic renal cell carcinoma | - |
dc.subject.keyword | sunitinib | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 10 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 237 | - |
dc.citation.endPage | 245 | - |
dc.identifier.bibliographicCitation | ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.10(3) : 237-245, 2014 | - |
dc.identifier.rimsid | 57058 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.